Table 1.

Participant characteristics

			Respondents	Non-respondents	P value
Demographic	Sex	Female	20 (46.5%)	12 (48%)	.91
		Male	23 (53.5%)	13 (52%)
	Race	African American	2 (4.7%)	4 (16%)	.08
		Asian/Pacific Islander	2 (4.7%)	0
		Caucasian	37 (86%)	12 (64%)
		Hispanic	1 (2.3%)	2 (8%)
		Other/multiple races	1 (2.3%)	3 (12%)
	SES (BSMSS)*		41.77	37.14	.18
Clinical	Assigned group	Control	21 (48.8%)	13 (52%)	.81
		Intervention	22 (51.2%)	12 (48%)
	Acute lymphoblastic leukemia		25 (58.1%)	22 (88%)	< .01
	Brain tumor		18 (41.9%)	3 (12%)
	Mean age at diagnosis, years		5.06 ± 2.88	4.58 ± 2.66	.50
	Mean age at enrollment, years		12.16 ± 2.29	11.76 ± 2.69	.53
	Mean time since treatment, years		4.28 ± 0.56	4.01 ± 0.49	.06
	Brain tumor group	Ependymoma	4 (9.3%)	0	.01
		Glioma	2 (4.7%)	0
		Medulloblastoma/PNET	12 (27.9%)	3 (12%)
	Mean Baseline IQ		106.21	98.52	.04

Abbreviations: PNET, primitive neuroectodermal tumor; SES, socioeconomic status.

*Barratt Simplified Measure of Social Status. Scores derived from maternal and paternal education and occupation; scores range from 8 to 66 with high being indicative of higher SES.